Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1. Оренбургский областной клинический онкологический диспансер, г. Ор енбург, Российская Федерация 2. Оренбургский государственный медицинский университет, г. Оренбург, Российская Федерация
Список исп. литературыСкрыть список 1. Злокачественные новообразования в России в 2019 году (заболеваемость и смертность). Под ред. А. Д. Каприна, В. В. Ста- ринского, Г. В. Петровой. М.: МНИОИ им. П.А. Герцена - филиал ФГБУ «НМИЦ радиологии» Минздрава России. 2020, 252 с. 2. Игнатьева В. И., Грецова О. П., Стенина М. Б., Омельяновский В. В., Деркач Е. В., Домбровский В. С. Социально-экономиче- ское бремя рака молочной железы в РФ. Медицинские технологии. Оценка и выбор. 2016;(4(26)):32–49. 3. Стенина М. Б., Жукова Л. Г., Королева И. А., Пароконная А. А., Семиглазова Т. Ю., Тюляндин С. А. и др. Практические реко- мендации по лекарственному лечению рака молочной железы. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2020;10(3s2):150–187. https://doi.org/10.18027/2224-5057-2020-10-3s2-09 4. Von Waldenfels G, Loibl S, Furlanetto J, Machleidt A, Lederer B, Denkert C, et al. Outcome after neoadjuvant chemotherapy in elderly breast cancer patients – a pooled analysis of individual patient data from eight prospectively randomized controlled trials. Oncotarget. 2018 Mar 16;9(20):15168–15179. https://doi.org/10.18632/oncotarget.24586 5. Рощин Е. М., Зубанова А. А, Колядина И. В., Комов Д. В., Вишневская Я. В., Ожерельев А. С. и др. Лечебный патоморфоз как критерий эффективности лечения и прогноза рака молочной железы. Медицинский альманах. 2010;(3(12)):48–53. 6. Павликова О. А., Колядина И. В., Комов Д. В., Вишневская Я. В., Поддубная И. В. Факторы-предикторы достижения полного Research and Practical Medicine Journal 2021, Vol. 8, No. 4, P. 53-64 E. Yu. Zubareva , M. A. Senchukova, E. V . Virich, M. R. Zubarev, M. A. Goncharova / Serum HIF-1α and TGFβ1 lev els depending on the clinical and morphological characteristics of breast cancer and sensitivity of tumor to neoadjuvant c hemotherapy 61 лекарственного патоморфоза при неоадъювантной химиотерапии первичнооперабельного рака молочной железы. Совре- менная онкология. 2017;19(1):24–29. 7. Kurozumi S, Inoue K, Takei H, Matsumoto H, Kurosumi M, Horiguchi J, et al. ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide concomitant with trastuzumab. BMC Cancer. 2015 Sep 7;15:622. https://doi.org/10.1186/s12885-015-1641-y 8. Dave RV, Millican-Slater R, Dodwell D, Horgan K, Sharma N. Neoadjuvant chemotherapy with MRI monitoring for breast cancer. Br J Surg. 2017 Aug;104(9):1177–1187. https://doi.org/10.1002/bjs.10544 9. Sasanpour P, Sandoughdaran S, Mosavi-Jarrahi A, Malekzadeh M. Predictors of Pathological Complete Response to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients. Asian Pac J Cancer Prev. 2018 Sep 26;19(9):2423–2427. https://doi.org/10.22034/APJCP.2018.19.9.2423 10. Karak SG, Quatrano N, Buckley J, Ricci A. Prevalence and significance of perineural invasion in invasive breast carcinoma. Conn Med. 2010 Jan;74(1):17–21. 11. Hwang HW, Jung H, Hyeon J, Park YH, Ahn JS, Im Y-H, et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat. 2019 Jan;173(2):255–266. https://doi.org/10.1007/s10549-018-4981-x 12. Schlotter CCM, Tietze L, Vogt U, Heinsen CV, Hahn A. Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival. Horm Mol Biol Clin Investig. 2017 Sep 22;32(2). https://doi.org/10.1515/hmbci-2017-0022 13. Nakashoji A, Matsui A, Nagayama A, Iwata Y, Sasahara M, Murata Y. Clinical predictors of pathological complete response to neoadjuvant chemotherapy in triple-negative breast cancer. Oncol Lett. 2017 Oct;14(4):4135–4141. https://doi.org/10.3892/ol.2017.6692 14. An YY, Kim SH, Kang BJ. Residual microcalcifications after neoadjuvant chemotherapy for locally advanced breast cancer: comparison of the accuracies of mammography and MRI in predicting pathological residual tumor. World J Surg Oncol. 2017 Nov 6;15(1):198. https://doi.org/10.1186/s12957-017-1263-8 15. Mazari FAK, Sharma N, Dodwell D, Horgan K. Human Epidermal Growth Factor 2-positive Breast Cancer with Mammographic Microcalcification: Relationship to Pathologic Complete Response after Neoadjuvant Chemotherapy. Radiology. 2018 Aug;288(2):366–374. https://doi.org/10.1148/radiol.2018170960 16. Zhu W, Xu B. Association of Pretreatment Anemia with Pathological Response and Survival of Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: A Population-Based Study. PLoS One. 2015;10(8):e0136268. https://doi.org/10.1371/journal.pone.0136268 17. Новиков В. Е., Левченкова О. С. Гипоксией индуцированный фактор (HIF-1α) как мишень фармакологического воздействия. Обзоры по клинической фармакологии и лекарственной терапии. 2013;11(2):8–16. 18. Zonneville J, Safina A, Truskinovsky AM, Arteaga CL, Bakin AV. TGF-β signaling promotes tumor vasculature by enhancing the pericyte- endothelium association. BMC Cancer. 2018 Jun 19;18(1):670. https://doi.org/10.1186/s12885-018-4587-z 19. Cai F-F, Xu C, Pan X, Cai L, Lin X-Y, Chen S, et al. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget. 2016 Nov 22;7(47):77793–77806. https://doi.org/10.18632/oncotarget.12796 20. Sundqvist A, Vasilaki E, Voytyuk O, Bai Y, Morikawa M, Moustakas A, et al. TGFβ and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness. Oncogene. 2020 May;39(22):4436–4449. https://doi.org/10.1038/s41388-020-1299-z 21. Vitiello GAF, Amarante MK, Oda JMM, Hirata BKB, de Oliveira CEC, Campos CZ, et al. Transforming growth factor beta 1 (TGFβ1) plasmatic levels in breast cancer and neoplasia-free women: Association with patients’ characteristics and TGFB1 haplotypes. Cytokine. 2020 Mar 28;130:155079. https://doi.org/10.1016/j.cyto.2020.155079 22. Papadopoulou E, Anagnostopoulos K, Tripsianis G, Tentes I, Kakolyris S, Galazios G, et al. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism. Neoplasma. 2008;55(3):229–238. 23. J, Zavadova E, Halaska MJ, Strnad P, Fucikova T, Rob L. Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol. 2008;29(6):613–636. 24. C, Herrera AC, Victorino VJ, Aranome AMF, Cecchini R. Screening of circulating TGF-β levels and its clinicopathological significance in human breast cancer. Anticancer Res. 2013 Feb;33(2):737–742. 25. Huang F, Shi Q, Li Y, Xu L, Xu C, Chen F, et al. HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer. Cancer Res. 2018 Nov 1;78(21):6073–6085. https://doi.org/10.1158/0008-5472.CAN-18-0136 26. Франциянц Е. М., Саманева Н. Ю., Владимирова Л. Ю., Сторожакова А. Э., Калабанова Е. А., Кабанов С. Н. и др. Содержа- ние факторов роста и прогрессирования в крови больных местнораспространенным раком молочной железы в процессе неоадъювантной химиотерапии. Южно-Российский онкологический журнал/ South Russian Journal of Cancer. 2021;2(3):6-12. https://doi.org/10.37748/2686-9039-2021-2-3-1 27. Bottini A, Berruti A, Brizzi MP, Bersiga A, Generali D, Allevi G, et al. Pretreatment haemoglobin levels significantly predict the tumour response to primary chemotherapy in human breast cancer. Br J Cancer. 2003 Sep 15;89(6):977–982. https://doi.org/10.1038/sj.bjc.6601216 28. Beresford MJ, Burcombe R, Ah-See ML, Stott D, Makris A. Pre-treatment haemoglobin levels and the prediction of response to neoadjuvant chemotherapy in breast cancer. Clin Oncol (R Coll Radiol). 2006 Aug;18(6):453–458. https://doi.org/10.1016/j.clon.2006.04.006 29. Bahhnassy A, Mohanad M, Shaarawy S, Ismail MF, El-Bastawisy A, Ashmawy AM, et al. Transforming growth factor-β, insulin-like growth factor I/insulin-like growth factor I receptor and vascular endothelial growth factor-A: prognostic and predictive markers in triple- negative and non-triple-negative breast cancer. Mol Med Rep. 2015 Jul;12(1):851–864. https://doi.org/10.3892/mmr.2015.3560 30. Ciftci R, Tas F, Yasasever CT, Aksit E, Karabulut S, Sen F, et al. High serum transforming growth factor beta 1 (TGFB1) level predicts better survival in breast cancer. Tumour Biol. 2014 Jul;35(7):6941–8. https://doi.org/10.1007/s13277-014-1932-y